0000-0002-8355-2921 About
I have been at the forefront of biopharmaceutical innovation with over 23 years of experience, currently leading as Director and Head of Discovery Biology Division at Cipla R&D Centre. My career began as a Research Scientist, progressing to significant leadership roles due to my expertise in oncology, autoimmune disorders, pulmonary hypertension, neurology, and infectious diseases. I have a Ph.D. in Life Sciences from the National Institute for Research in Reproductive Health (ICMR) and an MBA with a focus on Leadership, Strategy, and Finance.
At Cipla, I have been instrumental in establishing robust in vitro and in vivo assay platforms, which have been crucial for the development of therapies and diagnostics.
I have co-authored about 22 US patents, contributing to novel pharmaceutical compositions and treatments. My research findings have been published in several peer-reviewed journals and include presentations at major international conferences, underscoring my role as a thought leader in the pharmaceutical industry.
I am completely committed to quality and regulatory standards and ensure high compliance and efficiency in Cipla's operations, aligning with global best practices.
Employment
-
Cipla (India) Director
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (10)
- Ketorolac modulates Rac-1/HIF-1α/DDX3/β-catenin signalling via a tumor suppressor prostate apoptosis response-4 (Par-4) in renal cell carcinoma Save
- Prostate Apoptosis Response-4 (Par-4): A Novel Target in Pyronaridine-Induced Apoptosis in Glioblastoma (GBM) Cells Save
- Prostate Apoptosis Response-4: a Therapeutic Target for Malignant Gliomas Save
- Abstract 2013: A carbonic anhydrase inhibitor methazolamide potentiates efficacy of gemcitabine by modulating anti-proliferative activity and cancer stem cell markers in pancreatic carcinoma Save
- Abstract 251: Anti-malarial drug Pyronaridine modulates microenvironment leading to potent anti-cancer activity against GBM Save
- Abstract 2316: In vitro and in vivo anticancer potential of adapalene, a third-generation retinoid against bladder cancer Save
- Abstract B141: Repurposing of ketorolac for the treatment of renal cell carcinoma (RCC) Save
- Characterization of Peptide 20–30 of Follicle Stimulating Hormone Receptor as an Antagonist of Receptor Activity: Significance of Charged Residues Save
- Identification of the region 285–309 of follicle stimulating hormone receptor as a bioneutralizing epitope Save
- Detailed analysis of the region 9–30 of rat follicle stimulating hormone receptor: Identification of peptide 20–30 as a potential hormone binding inhibitor Save